scholarly journals Elevated Risk of Papillary Thyroid Cancer in Guatemalan Patients with Hashimoto Thyroiditis

2021 ◽  
Vol 13 (1) ◽  
pp. 1-3
Author(s):  
Ana Mejia-Pineda ◽  
Marco Antonio Peñalonzo ◽  
Maria-Lorena Aguilera-Arevalo
2012 ◽  
Vol 398 (3) ◽  
pp. 389-394 ◽  
Author(s):  
Aleksander Konturek ◽  
Marcin Barczyński ◽  
Wojciech Wierzchowski ◽  
Małgorzata Stopa ◽  
Wojciech Nowak

2014 ◽  
Vol 33 (7) ◽  
pp. 1299-1303 ◽  
Author(s):  
Harumi Koibuchi ◽  
Kiyoka Omoto ◽  
Noriyoshi Fukushima ◽  
Tomonori Toyotsuji ◽  
Nobuyuki Taniguchi ◽  
...  

Head & Neck ◽  
2010 ◽  
Vol 33 (5) ◽  
pp. 691-695 ◽  
Author(s):  
Kyung Won Kim ◽  
Young Joo Park ◽  
Eun Hye Kim ◽  
So Yeon Park ◽  
Do Joong Park ◽  
...  

2015 ◽  
Vol 64 (8) ◽  
pp. 1011-1019 ◽  
Author(s):  
Snezana Zivancevic-Simonovic ◽  
Olgica Mihaljevic ◽  
Ivana Majstorovic ◽  
Suzana Popovic ◽  
Slavica Markovic ◽  
...  

2017 ◽  
Vol 37 (5) ◽  
pp. 393-400
Author(s):  
J. Liang ◽  
W. Zeng ◽  
F. Fang ◽  
T. Yu ◽  
Y. Zhao ◽  
...  

Il carcinoma papillare (PTC) è il più comune tumore maligno della ghiandola tiroide. L’effetto della concomitante presenza della tiroidite di Hashimoto (HT) e del PTC è ancora oggetto di studio. Scopo di questo studio è analizzare la coesistenza di una concomitante HT circa l’outcome prognostico e eventuali associazioni clinico-patologiche. Abbiamo raccolto ed analizzato i dati demografici e clinicopatologici di 1392 pazienti che sono stati sottoposti a chirurgia nel nostro ospedale dal 2007 al 2016. Fra i 1392 pazienti con PTC, la percentuale di coesistente HT era del 25,6%. Vi erano differenze significative tra i due gruppi nei livelli medi di ormone tireostimolante (3.27 vs. 2.41μIU/L, p < 0.01), anticorpi anti tireoperossidasi (110.31 vs. 131.2U/ml, p < 0.01) e anticorpi anti tireoglobulina (131.90 vs. 113.53 ng/ ml, p < 0.01) I pazienti con PTC e HT avevano le seguenti caratteristiche se comparate con quelle dei pazienti senza HT: tumori di dimensioni più piccole (p < 0.01), predominanza del sesso femminile (p < 0.01) ed un piu’ alto tasso di multifocalita’(p = 0.024). Inoltre, i pazienti con HT avevano un tasso significativamente basso di metastasi linfonodali (LNM) ed uno stadio di TNM più elevato rispetto ai pazienti senza HT (tutti p < 0.01). L’analisi multivariata ha evidenziato come età e multifocalità erano significativamente associate con metastasi nel compartimento centrale nei pazienti con HT (p < 0.01, p = 0.019, rispettivamente). L’invasione extratiroidea ed i livelli di TSH erano fattori significativamente indipendenti per le metastasi linfonodali laterocervicali nei pazienti con HT (p < 0.008, p = 0.04, rispettivamente). HT era associata ad un maggior rischio di sviluppare PTC. La coesistenza di HT in pazienti con PTC favoriva un miglior outcome clinico rispetto a quei pazienti con PTC ma senza HT. La tiroidectomia totale associata allo svuotamento del compartimento centrale deve essere la prima scelta chirurgica nei pazienti con PTC e HT.


2020 ◽  
Vol 16 (33) ◽  
pp. 2735-2746
Author(s):  
Jiahui Wang ◽  
Xianfeng Jiang ◽  
Guizhou Xiao ◽  
Weiping Zhou ◽  
Yan Hu

Background: Thyroglobulin washout of fine needle aspiration (FNA-Tg) has proved to be useful in detecting lymph node metastases from papillary thyroid cancer; however, the influences of thyroid gland, Hashimoto thyroiditis, serum thyroglobulin (Tg) and anti-TG antibody on the diagnostic performance of FNA-Tg are controversial. Patients & methods: We retrospectively collected the FNA-Tg results of 176 preoperative or postoperative patients (356 lymph nodes) who finally were diagnosed with papillary thyroid cancer. The diagnostic abilities of FNA-Tg were evaluated and compared under different circumstances. Results: The diagnostic performance of FNA-Tg was uninfluenced irrespective of the status of thyroid gland or serum anti-TG antibody. However, high serum Tg was positively correlated with FNA-Tg (Exp(B) = 1.57; 95% CI: 1.209–2.309; p = 0.001). Conclusion: FNA-Tg was an excellent diagnostic tool, but it should be interpreted with caution only if serum Tg is higher than 10 ng/ml.


Endocrinology ◽  
2020 ◽  
Vol 161 (10) ◽  
Author(s):  
Zhong-Wu Lu ◽  
Jia-Qian Hu ◽  
Wan-Ling Liu ◽  
Duo Wen ◽  
Wen-Jun Wei ◽  
...  

Abstract The incidence of papillary thyroid cancer (PTC) with concomitant Hashimoto thyroiditis (HT) is increasing. Interleukin (IL)-10 is a cytokine previously reported to be elevated in this condition. Evidence from multiple human malignancies showed IL-10 participated in tumor immunity and exhibited therapeutic potential. The aim of this study is to investigate whether IL-10 interferes with tumor immunity in PTC with concomitant HT. Expression of IL-10 and major histocompatibility complex (MHC) class Ⅰ were compared with PTC tissues with or without concomitant HT. PTC cell lines K1 and TPC-1 were stimulated with IL-10 and analyzed for MHC class Ⅰ expression afterward. T-cell activation, production of IL-2 and interferon (IFN)-γ and programmed death-1 (PD-1) expression were assessed by coculture of donor peripheral blood lymphocytes (PBLs) with IL-10-pretreated PTC cells. Programmed death-ligand 1 (PD-L1) expression was measured in PTC tissues and IL-10-pretreated cells of K1 and TPC-1. Increased levels of IL-10 and MHC class Ⅰ were observed in PTC with concomitant HT. IL-10 stimulation increased MHC class Ⅰ expression of PTC cells in vitro. Coculture of PBLs with IL-10-pretreated PTC cells enhanced T-cell activation (% cluster of differentiation [CD]25+ of CD3+T cells) and increased IL-2 production along with decreased IFN-γ secretion and PD-1 expression. Reduced PD-L1 expression was seen in PTC + HT tissue samples and IL-10-stimulated PTC cell lines. Elevated IL-10 expression in PTC with concomitant HT restores MHC class Ⅰ expression and interferes with tumor immunity. The potential mechanism of IL-10 in tumor immunity needs further investigation.


Sign in / Sign up

Export Citation Format

Share Document